The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was little interest in the drug, particularly in the medical community.
T. brevifolia is a slow-growing tree that is found primarily in the coastal areas of the Northwest of the USA. The potential medicinal properties of the plant had never been investigated. The assignment of the plant to the Research Triangle Institute (RTI) International by Dr Hartwell was not entirely serendipitous. When the original cytotoxicity tests were performed with crude extracts by NCI contractors, some of the samples showed cytotoxicity against 9 KB cell cultures that had been derived from a human cancer of the nasopharynx. Drs Wall and Wani, medicinal chemists who worked at RTI International, had noted an excellent correlation between L1210 (lymphoid leukemia in mice) in-vivo activity and the 9 KB cytotoxicity assay when studying camptothecin [3] . Accordingly, they had requested Dr Hartwell to assign to them as many 9 KB active plant extracts as possible.
Extraction and isolation
Initial samples of T. brevifolia arrived at RTI International in 1964. The isolation procedure finally adopted after several unsuccessful trials is shown in Chart 1 and Chart 2. Extraction was carried out by ethanol with partition of the ethanolic residue between water and chloroform. Purification and isolation utilized a large number of Craig countercurrent distribution treatments, the last of which involved a 400-tube Craig countercurrent distribution. In this manner, B0.5 g of Taxol ( Fig. 1 ) [1] was isolated starting with 12 kg of air-dried stem and bark from T. brevifolia. The yield was B0.004%. All the various steps were monitored by an in-vivo bioassay that involved the inhibition of the solid tumor known as Walker-256 intramuscular rat carcinosarcoma. As shown in Chart 2, increased purification was accompanied by increased antitumor activity at lower doses. The isolation steps were laborious, but because of the mild countercurrent distribution methodology, losses or alterations of the active constituent were avoided. Much simpler procedures were subsequently developed both at RTI International and elsewhere.
Structural determination of Taxol
As soon as Taxol had been isolated in pure form, the structure of the compound was investigated using available spectroscopic methods. Although methods for ultraviolet, infrared, and mass spectrometry were at a reasonably advanced stage in the late 1960s, nuclear magnetic resonance (NMR) spectroscopy was relatively primitive compared with the sophisticated instrumentation and procedures available now.
The determination of the structure of Taxol proved to be an extremely difficult task. The molecular formula of Taxol was determined to be C 47 H 51 NO 14 by a combination of mass spectrometry and elemental analysis [1] . Data from 1H NMR spectrometry and biogenetic considerations suggested that Taxol was a diterpenoid possessing a taxane skeleton to which several esters were attached.
Because of the very limited quantity of Taxol available at the time and its evident structural complexity, attempts were made to prepare derivatives suitable for X-ray analysis. Although a number of crystalline, halogenated derivatives were obtained, none had properties suitable for X-ray analysis. Taxol was therefore subjected to a mild base-catalyzed methanolysis at 01, yielding a nitrogen-containing a-hydroxyl ester (2, C 17 The ester 2 was converted into a p-bromobenzoate 4 and the tetraol 3 into a 7,10-bisiodoacetate 5 (Fig. 2) , and the structures of the halogenated derivatives of 2 and 3 were determined by X-ray analysis. For full details of X-ray analysis and physical constants of compounds 2-5 (cf. Wani et al. [1] ).
The structures of the methyl ester 2 and the tetraol 3 (10deacetylbaccatin III) ( Fig. 2) were derived from the radiographic structures of 4 and 5, respectively. Compound 2 is the methyl ester of N-benzoyl-b-phenylisoserine. The final structure of 1 required the placement of the two hydrolyzed ester functions of 1 on the tetraol 3. Taxol could not be oxidized by neutral, activated manganese dioxide, indicating that the two esters were located at the allylic positions 10 and 13. The chemical shifts of the protons at C-10 and C-13 were also in accord with this observation. Oxidation of 1 with activated manganese dioxide under mild basic conditions (pH of the aqueous suspension 8.0) in acetone yielded the 7b-hydroxyl conjugated ketone 6 ( Fig. 2 ). The molecular composition by high-resolution mass spectrometry was in accordance with the formula C 31 H 36 O 11 , suggesting that it was formed by the loss of the nitrogen-containing a-hydroxyl ester function and oxidation of the allylic a-hydroxyl group released. The ultraviolet (l max MeOH, 272 nm, E 4800) and infrared spectra (n max CHCl 3 1680/cm) were in complete accord with this structure and ruled out the alternative D 11 -9,10-dioxo formulation. In addition, the 1H NMR spectrum of 6 clearly showed the presence of a singlet because of the C-10 proton at d6.46 as required by formulation 6.
Biological activity of crude and purified Taxol
The crude extracts of T. brevifolia were subjected to a number of assays in rodent leukemias and solid tumors. In early work, it was found that the crude extracts were active not only in the Walker tumor inhibition assay but also had modest activity in L1210 leukemia cells and particularly high activity in the 1534 (P4) leukemia assay. The latter assay is a life prolongation assay in mice, and it had been used previously by scientists at Eli Lilly during the isolation of the vinca alkaloids that showed high activity in this system. The same was noted for Taxol, with T/C values in the P4 system in excess of 300, even with crude extracts. The activity of pure Taxol in a number of in-vivo rodent assays is shown in Table 1 .
Activity of Taxol against solid tumors
Development efforts with Taxol stopped for nearly a decade because of its mediocre activity in P388 and L1210 leukemia assays, poor water solubility, and anticipated supply problems because of low yields from natural sources, and inaccessibility by total synthesis, because of structural complexity. There was a revival of interest in Taxol when it was discovered that Taxol showed impressive activity against the relatively resistant murine B16 melanoma and a panel of human solid tumors carried as xenografts in mice ( Table 1 ). Cabazitaxel (8) 1'
Mechanism of action of Taxol
Structures of Taxol, Taxotere, and Cabazitaxel. , requesting that she study the mechanism of action of Taxol. Although the landmark paper describing the initial isolation of Taxol and determination of its structure was published in 1971 [1] , Dr Horwitz was completely unaware of this molecule. Her publications with camptothecin [4] , the epipodophyllotoxins [5] , and bleomycin [6] showed her deep interest in natural products that had antitumor activity. In addition, she was the recipient of a Cancer Research Emphasis Grant. The latter was an unusual funding mechanism, somewhere between a contract and a grant. She had been requested by the NCI to study other compounds but had turned them down because often they were a well-studied drug with a new substitution, such as a fluorine or bromine. Taxol was quite different; it was a complex molecule whose structure Dr Horwitz found intriguing. This unusual chemical structure was a diterpene with a taxane ring, with a fourmembered oxetane ring and an ester side chain at position C-13, the latter being essential for biological activity (Fig. 2) . She had a new graduate student at the time, Peter Schiff (please see the article by Schiff et al. on pp. 502-511 of this issue) [7] , who was searching for a good thesis topic. Together, they decided they would start exploring the mechanism of action of Taxol and requested 10 mg from the NCI. If the project did not look interesting after a month, they would drop it; otherwise, they hoped that it would provide a good thesis project. As it turned out, it was an excellent thesis topic and to this day, Taxol continues to stimulate interesting scientific questions in addition to being an important component of drug combinations. The drug has been provided to over 1 million patients.
The Horwitz lab verified that Taxol was highly cytotoxic, inhibiting the growth of HeLa cells at nanomolar concentrations. Although cells went through a perfectly normal S phase in the presence of the drug, it became clear that Taxol blocked cells in the metaphase of the cell cycle. However, what was most exciting and unusual was that Taxol had the capacity to enhance the polymerization of stable microtubules. In contrast to the vinca alkaloids, vincristine and vinblastine, which inhibit microtubule polymerization and are important antitumor drugs used for the treatment of leukemias and lymphomas, respectively, Taxol enhanced the polymerization of tubulin in an in-vitro system with purified bovine brain tubulin in the absence of GTP that is normally required. These polymerized microtubules were stable to low temperatures and calcium, conditions that depolymerize normal microtubules [8] . Studies in HeLa cells made it clear that the effects observed in an in-vitro system carried over into living cells, where obvious alterations could be observed in the microtubule cytoskeleton after Taxol treatment. The drug reorganized the microtubule cytoskeleton so that large bundles of microtubule were clearly visible ( Fig. 3) , proliferation was inhibited, and the cells were unable to migrate [9] . The formation of stable microtubule bundles in cells is a hallmark of Taxol treatment and observed in the white blood cells of patients being treated with the drug. In many ways, Taxol caused what could be referred to as a paralyzed microtubule cytoskeleton. More extensive studies with Taxol indicated that the mechanisms by which Taxol induced cell death were concentration dependent. At Taxol concentrations of more than 10 nmol/l, cells were 
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The effect of Taxol on the microtubule cytoskeleton in A549 cells.
Nature as a remarkable chemist Wani and Horwitz 485 blocked in mitosis, whereas at lower concentrations, aberrant mitosis led to cell death [10] [11] [12] and suppression of microtubule dynamics [13, 14] . Although it was immediately clear to biochemists and cell biologists that Taxol would be an excellent tool for studying microtubule polymerization and the role of microtubules in a variety of cellular processes, there was no interest in the drug by pharmaceutical companies. The interest of biologists in the drug was immediately observed at the NCI, where requests for the drug increased markedly.
In 1979, the Horwitz laboratory published its first paper on Taxol describing its unique mechanism of action [8] .
On the basis of the good activity the drug had shown against B16 melanoma, the NCI selected the drug for clinical development. The collaboration between the USDA and the NCI had not produced any new anticancer drugs, and Taxol was its last hope. Taxol also showed good activity against some human xenografts, particularly the MX-1 mammary tumor. The fact that the Horwitz laboratory had published that Taxol was a prototype for a new class of antitumor drugs also helped to set the stage for preclinical toxicology studies to begin at the NCI.
Although there was no question that Taxol had a marked effect on the microtubule cytoskeleton, it was not a simple task to decipher the mechanism by which that occurred. Taxol did not form a covalent bond with tubulin, making it difficult to decipher the interaction of the drug with its target protein in the test tube or in a cell. The Horwitz laboratory decided that the best approach was to use photoaffinity-labeled Taxol analogs, that, in the presence of light, would form covalent bonds with tubulin. Using three different analogs, three defined sites in b-tubulin were identified as binding sites for Taxol. CNBr and enzymatic digestions of the drug-tubulin complex plus N-terminal amino acid sequencing identified three points of interaction between the drug and b-tubulin [15] .
At the same time, Drs Eva Nogales and Ken Downing who were working at Lawrence Berkeley National Laboratory in California and performing electron crystallography of zinc sheets of tubulin stabilized with Taxol, developed a three-dimensional model of Taxol with an a-tubulin, b-tubulin heterodimer that was fitted to a 3.7 Å density map [16] . This was significant and important research that considerably enhanced our understanding of how small molecules interacted with tubulin. There was good agreement between the results obtained with photoaffinity analogs and electron crystallography. Since then, many laboratories have contributed toward our understanding of the mechanism of action of Taxol. By incorporating hydrogen/deuterium exchange and mass spectrometry into experiments, insights can be gained into the conformational and allosteric changes that Taxol induces in microtubules [17] .
Although originally there was little interest in Taxol as an antitumor drug, its success in the clinic has made small molecules that interact with microtubules of great interest. Today, there are a number of molecules of natural product origin that stabilize microtubules. Of particular interest is the fact that although these compounds all have distinct chemical structures and come from diverse natural products such as plants, bacteria, coral, and sponges, they all target and stabilize microtubules. One such molecule, the epothilone analog, ixabepilone (Ixempra), isolated from a bacteria, has already been FDA approved for the treatment of advanced breast cancer, and other molecules, all of natural product origin, that interact with the tubulin/microtubule system are in the pipeline.
Clinical development
Chemists were well aware of the extreme hydrophobicity of the Taxol molecule, which became a serious problem when attempting to formulate the drug for clinical use.
The drug was prepared in Cremophor EL, that alone, in the absence of Taxol, could cause toxicities, such as a decrease in blood pressure in dogs. Another serious problem was the severe hypersensitivity reactions that were experienced by the first patients to receive Taxol. In fact, one of the first patients who received Taxol died of an anaphylactic shock and this would have been sufficient to block further clinical studies with most drugs. There was a 5-year hiatus between 1983 and 1988 when the drug was not used in any clinical trials. During this period, oncologists, formulation chemists, and pharmacologists worked together to find a solution to the allergic reactions being encountered so that the drug could again be introduced into clinical trials. This time the drug was administered to patients who were pretreated with antihistamines and steroids and who also received the drug over a 24 h period, instead of as a bolus, the way the first patient did. Another serious problem was a scarcity of drug as it took the bark of a mature yew tree (200 years old) to provide sufficient drug to treat a single patient with breast cancer, and when the bark was removed, the tree died. The collaboration of physicians and scientists was responsible for moving Taxol forward.
Once the drug was administered with the pre-treatment regimen, it became clear that it had good clinical activity in advanced drug-refractory ovarian carcinoma [18] and metastatic breast carcinoma [19] . Although all of the clinical studies had been carried out under the auspices of the NCI, the latter was not a drug company and incapable of developing the drug further. As no patents had been taken out on the chemical structure of the drug or its mechanism of action, the compound was not attractive to pharmaceutical companies. Therefore, the NCI advertised a Cooperative Research and Development Agreement that was awarded to Bristol-Myers Squibb. Much to their credit, the company isolated sufficient drug from the bark of the yew tree for testing, and in 1992, on 29 December, the FDA approved Taxol for refractory ovarian cancer, in 1994 for breast carcinoma, and in 1999 for nonsmall cell lung carcinoma. Taxol has and continues to be an essential drug for the treatment of a variety of malignances and is still being tried in new combinations of antitumor drugs. Just this year, the FDA approved the supplemental New Drug Application of Abraxane (paclitaxel albumin-bound particles for injectable suspension) as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. Adenocarcinoma, a subtype of exocrine tumors, accounts for about 95% of cancers of the pancreas.
Nature has been a remarkable chemist, providing us with chemical structures no scientist could imagine. We anticipate that there are many more interesting molecules to be found, hopefully before much of the natural habitat of the earth has been destroyed.
